{"id":40009,"date":"2025-08-25T14:30:23","date_gmt":"2025-08-25T06:30:23","guid":{"rendered":"https:\/\/flcube.com\/?p=40009"},"modified":"2025-08-25T14:30:24","modified_gmt":"2025-08-25T06:30:24","slug":"vibrant-therapeutics-secures-multi-million-series-a-funding-to-advance-intelligent-macromolecule-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40009","title":{"rendered":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs"},"content":{"rendered":"\n<p>Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company&#8217;s core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.<\/p>\n\n\n\n<p><strong>Company Background and Leadership<\/strong><br>Founded in 2019 by Dr. Wang Luquan, a co-founder of GenScript, Vibrant Therapeutics&#8217; core leadership team has over 20 years of experience in macromolecule drug R&amp;D on average. Team members have held key positions at renowned pharmaceutical and biotech companies such as Schering-Plough, Merck, and GenScript.<\/p>\n\n\n\n<p><strong>Proprietary Platform and Future Plans<\/strong><br>Vibrant Therapeutics&#8217; intelligent molecular design platform employs a &#8220;wet-dry combination&#8221; R&amp;D model, integrating computational prediction with experimental validation. This efficient, closed-loop process accelerates drug candidate screening and optimization, addressing unmet clinical needs. The funding will also support talent team expansion and the advancement of proprietary projects.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40012,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,4307],"class_list":["post-40009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-vibrant-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company&#039;s core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40009\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs\" \/>\n<meta property=\"og:description\" content=\"Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company&#039;s core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40009\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T06:30:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-25T06:30:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs\",\"datePublished\":\"2025-08-25T06:30:23+00:00\",\"dateModified\":\"2025-08-25T06:30:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2505.webp\",\"keywords\":[\"Finance\",\"Vibrant Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40009#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40009\",\"name\":\"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2505.webp\",\"datePublished\":\"2025-08-25T06:30:23+00:00\",\"dateModified\":\"2025-08-25T06:30:24+00:00\",\"description\":\"Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company's core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40009\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40009#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company's core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40009","og_locale":"en_US","og_type":"article","og_title":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs","og_description":"Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company's core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.","og_url":"https:\/\/flcube.com\/?p=40009","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-25T06:30:23+00:00","article_modified_time":"2025-08-25T06:30:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40009#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40009"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs","datePublished":"2025-08-25T06:30:23+00:00","dateModified":"2025-08-25T06:30:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40009"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40009#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp","keywords":["Finance","Vibrant Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40009#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40009","url":"https:\/\/flcube.com\/?p=40009","name":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40009#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40009#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp","datePublished":"2025-08-25T06:30:23+00:00","dateModified":"2025-08-25T06:30:24+00:00","description":"Vibrant Therapeutics, an innovative biotech company specializing in next-generation intelligent macromolecule drugs, announced on August 25, 2025, the completion of its multi-million-dollar Series A funding rounds. The Series A+ round was led by Apricot Capital, while the Series A round was led by Trinity-fund with participation from existing investors, including Sequoia China. The funds will primarily be used to advance the company's core pipeline into global clinical trials and accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40009#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40009"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40009#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp","width":1080,"height":608,"caption":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40009#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vibrant Therapeutics Secures Multi-Million Series A Funding to Advance Intelligent Macromolecule Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40009"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40009\/revisions"}],"predecessor-version":[{"id":40013,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40009\/revisions\/40013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40012"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}